Giocon Pharma Limited - Due diligence report

A 360° intelligence report on Giocon Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and distress …

1996-02-06 Visakhapatnam, Andhra Pradesh Active Unlisted Active Compliant
Share
GP Giocon Pharma Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Giocon Pharma Limited — 360° Intelligence Report

Generated from MCA filings & public records
59/100
Trust Score
Moderate

Giocon Pharma Limited is assessed as Moderate with a Trust Score of 59/100. Giocon Pharma Limited is an active public limited indian non-government company incorporated in 1996, operating in the Pharma sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 18 Jul 2026 from the latest processed filings. Giocon Pharma Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Good
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
59/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
75/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
50/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Negative operating earnings - debt service depends on external support.
  • Elevated gearing (D/E 38%).
  • Working-capital cover adequate.

Charges position: 1 open (50.00 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
City Union Bank Limited1 48.0 cr
Compliance Score: 75/100 Low Risk
  • Company status is Active as per MCA.
  • Last balance sheet is for Mar 2023 - filings overdue.
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
RAMPRASADREDDY VENNAPUSA 01234567 Director 01/04/2018 6 yrs Approved
DATTATREYA SARMA ARADYULA 01234567 Director 01/04/2018 6 yrs Approved
SANKEERTH RAM TALLAPRAGADA 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • RAMPRASADREDDY VENNAPUSA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2017)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2019 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
1 allotment(s) · 0 transfer(s)

Promoters hold the largest single block of equity - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 50
Growth signals & trust indicators
Operating for 30+ years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
Statutory filings appear overdue.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence63/100
Review suggested
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment44/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 50.00 Lakh already registered.
  • Compliance record supports lending.
Investor view41/100
Limited indicators at present
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2023
Last AGM held
Annual general meeting
31 Mar 2023
Latest balance sheet
Filed with ROC
31 Jul 2020
Director appointed
DATTATREYA SARMA ARADYULA (Director)
Director ceased
AKHTAR UZZAMAN
29 Jan 2020
Director ceased
SEETARAMAIAH MANGALAPALLI
24 Dec 2019
Director appointed
RAMPRASADREDDY VENNAPUSA (Additional Director)
Director appointed
SANKEERTH RAM TALLAPRAGADA (Additional Director)
14 Nov 2018
Director ceased
VANKADARA ASWARTHAMMA
Director ceased
VANKADARA RAO VISVESWARA
29 Sep 2018
Director ceased
ARADHYULA APARNA
18 Dec 2017
Director ceased
DINESH KUMAR GADDE
Director ceased
MYNEPALLI KEDAR SHANKAR
Director ceased
ARADHYULA RAMAKRISHNA
20 May 2016
Director ceased
DWIBHASHYAM SESHA SAI
26 May 2015
Securities allotted
1273680 Equity Shares Without Differential Rights - 1.27 cr raised
10

Key Observations

Auto-generated from the data above
Revenue declined 1.42 over the last 4 financial year(s).
Net profit margin moved from 2.1x to 24%.
Debt-to-equity stands at 0.86 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold the largest single block of equity as per the FY 2019 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Shivcon Pharma Private Limited U24230DL2016PTC291361 Delhi, Delhi, India
Soranus Lifesciences Private Limited U24230GJ2011PTC067578 Ahmedabad, Gujarat, India
Dolce Pharmaceuticals Private Limited U24200MH1994PTC083218 Boisar, Maharashtra, India
Indu Pharma Private Limited U24239TG2004PTC043904 Balanagar, Hyderabad - 37., Andhra Pradesh, India
Celeste Life Sciences Private Limited U24233DL2012PTC244947 Delhi, Delhi, India
Innovation Organics India Private Limited U33111UP2010PTC042952 Kanpur, Uttar Pradesh, India
Darvish Pharma Private Limited U33100AS2017PTC017723 Guwahati, Assam, India
Malpro Silica Private Limited U14107TZ1985PTC001649 Tamilnadu, Tamil Nadu, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Giocon Pharma Limited before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Giocon Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Limited indicators at present. Growth score 40/100, margin trends, ownership structure and peer set for Giocon Pharma Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Review suggested. Trust score 59/100, distress signals and MSME payment-delay disclosures - know whether Giocon Pharma Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Giocon Pharma Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Giocon Pharma Limited an active company?

Giocon Pharma Limited has MCA status “Active” with a compliance score of 75/100 (Low Risk).

Is Giocon Pharma Limited financially healthy?

Giocon Pharma Limited has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Giocon Pharma Limited?

Its overall Trust Score is 59/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Giocon Pharma Limited?

Promoters hold the largest single block of equity - exact percentages are in the full report. 3 active director(s) are on record.

Does Giocon Pharma Limited have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Giocon Pharma Limited up to date with its ROC filings?

Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 75/100 (Low Risk).

Is it risky to lend to Giocon Pharma Limited?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.